Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study

Hypertension
George L BakrisINVEST Investigators

Abstract

The INternational VErapamil SR-Trandolapril study (INVEST) had 6400 of 22,576 (28.3%) participants with diabetes at entry. The objectives of this prespecified analysis were to compare antihypertensive treatment strategies in the diabetes cohort (verapamil SR-based [n=3169] versus atenolol-based [n=3231]) and identify predictors for the primary outcome (a composite of first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke). During a mean follow-up of 2.7 years, 913 participants with diabetes experienced a primary outcome event, with no significant difference between treatment strategies (14.6%, verapamil SR versus 13.9%; atenolol hazard ratio, 1.05; 95% confidence interval, 0.92 to 1.19). Risk for the primary outcome increased with presence of baseline heart failure, renal impairment, US residency, age, previous stroke/transient ischemic attack, previous myocardial infarction, peripheral vascular disease, or smoking. High systolic and diastolic pressures during follow-up also were associated with increased risk, as were low diastolic pressures. Antihypertensive treatment with a verapamil SR or atenolol strategy resulted in similar rates of cardiovascular outcomes in coronary artery disease (CAD) ...Continue Reading

Associated Clinical Trials

References

Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Apr 24, 2003·JAMA : the Journal of the American Medical Association·Henry R BlackUNKNOWN CONVINCE Research Group
Jul 10, 2003·JAMA : the Journal of the American Medical Association·Ihab Hajjar, Theodore A Kotchen
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Dec 25, 2003·Diabetes Care·UNKNOWN American Diabetes Association
Feb 27, 2004·The American Journal of Clinical Nutrition·Ian JanssenRobert Ross

❮ Previous
Next ❯

Citations

Jul 8, 2010·JAMA : the Journal of the American Medical Association·Rhonda M Cooper-DeHoffCarl J Pepine
Jan 15, 2011·Current Atherosclerosis Reports·Gianpaolo ReboldiPaolo Verdecchia
Jun 3, 2005·Current Diabetes Reports·Fadi El-AtatSamy I McFarlane
Sep 13, 2006·Current Hypertension Reports·Sameer StasJames Sowers
Jul 3, 2010·Journal of Human Hypertension·M R WeirJ R Sowers
Jan 19, 2005·The Journal of Clinical Hypertension·Marayann N Mugo, James R Sowers
May 30, 2009·Vascular Health and Risk Management·Gianpaolo ReboldiPaolo Verdecchia
Mar 7, 2014·Diabetology & Metabolic Syndrome·Patricio Lopez-JaramilloMiguel I Rodriguez-Alvarez
Nov 19, 2013·Journal of Hypertension·Costas TsioufisChristodoulos Stefanadis
Sep 10, 2014·Journal of Hypertension·Anna SoliniUNKNOWN Renal Insufficiency And Cardiovascular Events (RIACE) Study Group
Sep 28, 2014·The American Journal of Cardiology·David E Winchester, Carl J Pepine
Nov 17, 2010·Nature Reviews. Cardiology·Rhonda M Cooper-DeHoffCarl J Pepine
Oct 20, 2009·Journal of Hypertension·Giuseppe ManciaUNKNOWN European Society of Hypertension
Dec 31, 2010·Journal of Hypertension·Michel Burnier, Guido Grassi
Dec 6, 2011·Current Cardiology Reports·Gianpaolo ReboldiPaolo Verdecchia
Aug 21, 2012·Current Cardiology Reports·Mark L Lipman, Ernesto L Schiffrin
Nov 11, 2009·Expert Review of Cardiovascular Therapy·Rhonda M Cooper-DeHoffCarl J Pepine
Nov 11, 2009·Expert Review of Cardiovascular Therapy·Gianpaolo ReboldiPaolo Verdecchia
Jan 20, 2016·Expert Review of Cardiovascular Therapy·Daniel T LacklandAndrea D Boan
Jun 10, 2009·Expert Review of Cardiovascular Therapy·Jason H Karnes, Rhonda M Cooper-DeHoff
May 31, 2007·The Canadian Journal of Cardiology·Nadia A KhanUNKNOWN Canadian Hypertension Education Program
Oct 6, 2005·Seminars in Nephrology·Kenneth L Choi, George L Bakris
Sep 9, 2006·Endocrinology and Metabolism Clinics of North America·Karin Jandeleit-Dahm, Mark E Cooper
May 12, 2005·The Journal of Clinical Hypertension·Samy I McFarlaneJames R Sowers
Sep 6, 2008·The Journal of Clinical Hypertension·Roland E Schmieder, Luis M Ruilope
Aug 9, 2007·Journal of the Cardiometabolic Syndrome·Kazuo EguchiKazuomi Kario
Jul 20, 2006·The Journal of Clinical Hypertension·James R SowersUNKNOWN INCLUSIVE Investigators
Feb 14, 2006·The Journal of Clinical Hypertension·Sara Giunti, Mark Cooper
May 12, 2006·The Journal of Clinical Hypertension·Panteleimon A Sarafidis, George L Bakris
Jul 4, 2006·The American Journal of Cardiology·Jeanine AlbuUNKNOWN Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators
Dec 20, 2005·Disease-a-month : DM·John Brian Copley, Reinaldo Rosario
Aug 4, 2015·Journal of Hypertension·Iris WalravenGiel Nijpels
Jun 22, 2012·Annals of Medicine·Noël C Barengo, Jaakko O Tuomilehto
Feb 21, 2009·Journal of the American College of Cardiology·Rhonda M Cooper-DeHoffCarl J Pepine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.